Term Infants News Today

/CNW/ - Health Canada has accepted a New Drug Submission (NDS) for nirsevimab, the first investigational single-dose long-acting antibody designed for all...

FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants, if approvedNirsevimab delivered consistent protection of approximately 80% against medically attended RSV diseas...

FDA accepts nirsevimab application as first protective option against RSV disease for all infants Nirsevimab would be the first broadly protective option against RSV disease designed for all infants

Investegate announcements from AstraZeneca PLC, Beyfortus (nirsevimab) approved in EU

Investegate announcements from AstraZeneca PLC, Nirsevimab recommended for approval in EU by CHMP

New nirsevimab data analyses reinforce efficacy against RSVA prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory tract infections (LRTI), including hospitalizations, caused by respiratory syncytial virus (RSV)1Nirsevimab is the firs...

New nirsevimab data analyses reinforce efficacy against RSV A prespecified pooled analysis of Phase 3 and Phase 2b data demonstrated an efficacy of 79.5% against medically attended lower respiratory

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial - read this article along with other careers information, tips and advice on BioSpace

Nirsevimab significantly protected infants against RSV disease in Phase 3 trial Nirsevimab showed a 74.5% reduction in lower respiratory tract infections caused by RSV requiring medical care in healthy

Press release content from Globe Newswire. The AP news staff was not involved in its creation.